Q-omics provides the consensus-scored OR51F2 profile across patient tissues and cancer cell-line models. OR51F2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, OR51F2 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, OR51F2 RNA expression shows 6,219 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, PRAD, and STAD as cancer lineages where OR51F2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51F2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51F2 survival associations across molecular data types. OR51F2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51F2 RNA expression–survival associations across cancer types. High OR51F2 expression shows unfavorable associations in BLCA, CHOL, BRCA, MESO, COAD and KICH. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for OR51F2 RNA expression.
This table summarizes OR51F2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR51F2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51F2 shows higher tumor expression in PRAD. The PRAD box plot shows higher OR51F2 RNA expression in tumor versus normal tissue (log2 FC = +0.191, t-test p < 0.001).
This table shows molecular features associated with OR51F2 in patient tissues and cancer cell lines. In patient samples, OR51F2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR51F2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
